Mendus AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMMU.ST research report →
Companywww.mendus.com
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II MERECA clinical trial for the treatment of kidney cancer; and Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's products also comprise DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia; and Phase I/II ALISON clinical trial for the treatment of ovarian cancers.
- CEO
- Erik Manting
- IPO
- 2013
- Employees
- 28
- HQ
- Stockholm, SE
Price Chart
Valuation
- Market Cap
- $288.28M
- P/E
- -3.36
- P/S
- 0.00
- P/B
- 0.62
- EV/EBITDA
- -2.23
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -17.87%
- ROIC
- -19.27%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-113,258,000 · 11.79%
- EPS
- $-2.17 · 17.80%
- Op Income
- $-120,256,000
- FCF YoY
- -0.41%
Performance & Tape
- 52W High
- $10.98
- 52W Low
- $3.86
- 50D MA
- $4.88
- 200D MA
- $5.67
- Beta
- 0.71
- Avg Volume
- 34.19K
Get TickerSpark's AI analysis on IMMU.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our IMMU.ST Coverage
We haven't published any research on IMMU.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IMMU.ST Report →